Nuvalent Inc Class A NUVL
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Nuvalent Announces Closing of Upsized Public Offering of Common Stock
-
Nuvalent Announces Pricing of Upsized Public Offering of Common Stock
-
Nuvalent Announces Public Offering of Common Stock
-
Nuvalent Highlights Presentation of Clinical Data at ESMO 2024 for Parallel Lead Programs for ROS1 and ALK-positive NSCLC and Accelerated Development Timelines
-
Nuvalent Announces Publication in Cancer Discovery Detailing Design and Characterization of ALK-selective inhibitor NVL-655
-
Updated Data for Nuvalent's ALK-Selective Inhibitor, NVL-655, and ROS1-Selective Inhibitor, Zidesamtinib, Continue to Support Potential Best-in-Class Profiles
-
Nuvalent to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference
-
Nuvalent Highlights Pipeline Progress, Reiterates Key Anticipated Milestones, and Reports Second Quarter 2024 Financial Results
Trading Information
- Previous Close Price
- $103.50
- Day Range
- $101.68–105.28
- 52-Week Range
- $49.02–113.51
- Bid/Ask
- $101.89 / $104.93
- Market Cap
- $7.40 Bil
- Volume/Avg
- 308,522 / 468,732
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Nuvalent Inc is a clinical stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. All of the Company’s operations are in the United States. The company is engaged in developing small molecules that are designed to overcome the limitations of existing therapies for clinically proven kinase targets. The product candidates of the company include NVL-520, which is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC), NVL-655, which is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to address the combined medical need of treating tumors driven by HER2ex20.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Growth
- Total Number of Employees
- 115
- Website
- https://www.nuvalent.com
Comparables
Valuation
|
Metric
|
NUVL
|
PRLD
|
MGNX
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 10.66 | 0.60 | 3.89 |
Price/Sales | — | — | 5.66 |
Price/Cash Flow | — | — | — |
Price/Earnings
NUVL
PRLD
MGNX
Financial Strength
|
Metric
|
NUVL
|
PRLD
|
MGNX
|
|---|---|---|---|
Quick Ratio | 17.23 | 7.71 | 2.53 |
Current Ratio | 17.44 | 7.83 | 2.71 |
Interest Coverage | — | — | −128.87 |
Quick Ratio
NUVL
PRLD
MGNX
Profitability
|
Metric
|
NUVL
|
PRLD
|
MGNX
|
|---|---|---|---|
Return on Assets (Normalized) | −23.36% | −40.98% | −59.21% |
Return on Equity (Normalized) | −24.62% | −46.70% | −120.96% |
Return on Invested Capital (Normalized) | −28.80% | −44.57% | −102.88% |
Return on Assets
NUVL
PRLD
MGNX
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Novo Nordisk AS ADR
NVO
| Gbqnljbntn | Lqqn | $512.4 Bil | |||
| Vertex Pharmaceuticals Inc
VRTX
| Tlyjlmt | Rfsqnvw | $117.5 Bil | |||
| Regeneron Pharmaceuticals Inc
REGN
| Qsdnpmgb | Prglj | $111.6 Bil | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Jllxynb | Bszhjl | $34.4 Bil | |||
| argenx SE ADR
ARGX
| Wqnjcspz | Npfd | $33.0 Bil | |||
| BioNTech SE ADR
BNTX
| Kxmmtpnfz | Jzqhd | $29.2 Bil | |||
| Moderna Inc
MRNA
| Kmkmpsbn | Dlz | $23.1 Bil | |||
| United Therapeutics Corp
UTHR
| Vlhwqgxs | Mkfmk | $15.8 Bil | |||
| Biomarin Pharmaceutical Inc
BMRN
| Ndkgkzjv | Yfbyx | $13.2 Bil | |||
| Incyte Corp
INCY
| Kfgkcbjg | Rgnvyq | $13.0 Bil |
United States